Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Slides:

Advertisements

Similar presentations

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Advertisements

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia

Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Gupta V, Tallman MS, Weisdorf DJ

Admission of Hematopoietic Cell Transplantation Patients to the Intensive Care Unit at the Pontificia Universidad Católica de Chile Hospital Karen Escobar,

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,

Solid cancers after allogeneic hematopoietic cell transplantation

Superior Survival after Autologous vs

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience by Régis Peffault.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Endocrine Challenges—Thyroid Dysfunction,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance.

Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute

Betty T. Tran, Abigail Halperin, Jason W. Chien

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

A Population-Based Cohort Study of Late Mortality in Adult Autologous Hematopoietic Stem Cell Transplant Recipients in Australia Lesley J. Ashton, Renate.

Tyler G. Ketterl, Eric J. Chow, Wendy M

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome Kitsada Wudhikarn, Claudio G. Brunstein, Veronika.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Biology of Blood and Marrow Transplantation

High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors Auayporn Nademanee,

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

by Kaiwen Chen, Matthew P. Cheng, Sarah P

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Eric J. Chow, Kenneth Wong, Stephanie J. Lee, Kara L

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Gerard Socié, K. Scott Baker, Smita Bhatia

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Biology of Blood and Marrow Transplantation

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Saro H. Armenian, David Horak, Jessica M

National Cancer Institute–National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference.

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome Peggy A. Wu,

Bridge to transplant following Bv+Bs regimen.

Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study by Hesham M. Eissa, Lu Lu, Malek Baassiri,

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Presentation transcript:

Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study by Can-Lan Sun, Liton Francisco, Toana Kawashima, Wendy Leisenring, Leslie L. Robison, K. Scott Baker, Daniel J. Weisdorf, Stephen J. Forman, and Smita Bhatia Blood Volume 116(17):3129-3139 October 28, 2010 ©2010 by American Society of Hematology

Cumulative incidence of chronic health conditions after HCT Cumulative incidence of chronic health conditions after HCT. (A) Cumulative incidence of any chronic health conditions (grades 1-5) and severe or life-threatening chronic health conditions (grade 3 or 4) or death from a chronic health condition (grade 5) af... Cumulative incidence of chronic health conditions after HCT. (A) Cumulative incidence of any chronic health conditions (grades 1-5) and severe or life-threatening chronic health conditions (grade 3 or 4) or death from a chronic health condition (grade 5) after HCT. (B) Cumulative incidence of any chronic health conditions (grades 1-5) in allogeneic and autologous HCT recipients. (C) Cumulative incidence of chronic health conditions (grades 3-5) in allogeneic and autologous HCT recipients. Can-Lan Sun et al. Blood 2010;116:3129-3139 ©2010 by American Society of Hematology